Research Papers:

CD147 silencing inhibits tumor growth by suppressing glucose transport in melanoma

Juan Su, Tianyuan Gao, Minghao Jiang, Lisha Wu, Weiqi Zeng, Shuang Zhao, Cong Peng and Xiang Chen _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:64778-64784. https://doi.org/10.18632/oncotarget.11415

Metrics: PDF 2679 views  |   HTML 2301 views  |   ?  


Juan Su1,2, Tianyuan Gao1,3, Minghao Jiang1,4, Lisha Wu5, Weiqi Zeng1,2, Shuang Zhao1,2, Cong Peng1,2 and Xiang Chen1,2

1 Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China

2 Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China

3 Department of Dermatology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shanxi

4 Department of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China

5 Institute of Medical Science Research, Xiangya Hospital, Central South University, Hunan, China

Correspondence to:

Xiang Chen, email:

Cong Peng, email:

Keywords: melanoma; CD147; glycolysis; GLUT-1; PI3K/Akt pathway

Received: June 29, 2016 Accepted: August 15, 2016 Published: August 19, 2016


Melanoma is a very malignant disease and there are still no effective treatments. CD147 participates in the carcinogenesis of multiple human cancers and GLUT-1, as a glucose transporter, is associated with tumor growth. However, the function of CD147 and GLUT-1 in melanoma have not been completely understood. Thus, in this study we investigated the expression of CD147 and GLUT-1 in melanoma tissue, which were overexpressed compared with that in nevus tissue. In addition, CD147 and GLUT-1 were co-localized in the cytoplasm of human melanoma A375 cells. Immunoprecipitation proved that CD147 interacted with GLUT-1 at D105-199. Silencing CD147 by specific siRNA could downregulate GLUT-1 level via inhibiting PI3K/Akt signaling and decrease glucose uptake in A375 cells. In vivo experiments also supported that CD147 knockdown suppressed the tumor growth in melanoma subcutaneous mice model, observed by micro PET/CT. Our results could help validate CD147 as a new therapeutic target for treating melanoma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11415